Oncology Archives - Page 15 of 20

c-MET Related In Vivo Models

c-Met is a receptor tyrosine kinase, a/k/a hepatocyte growth factor receptor (HGFR). As a type of proto-oncogene, c-Met overexpression, amplification...

AACR 2023: Integrated platform enables KRAS-targeted drugs discovery

Discover our end-to-end KRAS services platform presented at AACR 2023! WuXi AppTec scientists have established a comprehensive panel of assays...

AACR 2023: Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma

In our latest AACR poster, WuXi AppTec scientists characterize the therapeutic potential of the antibody-drug conjugate (ADC) polatuzumab vedotin across...

AACR 2023: A tailored platform enables BRAF-targeted drug discovery and precision medicine

In our latest AACR poster, WuXi AppTec scientists showcase the development of a tailored platform of patient-derived xenograft (PDX) models...

Discovery Newsletter: April 2023

In this month’s newsletter, learn more about our comprehensive panel of CDK4/6 inhibitor-resistant breast cancer models and in vitro imaging...

BRAF-Related In Vivo Models

Discover our comprehensive platform of CDX and PDX tumor models, carrying BRAF mutations across multiple cancer types: 18 CDX models...

Xenograft and Syngeneic Tumor Models in Rats

Leverage our extensive panel of rat xenograft and syngeneic tumor models. Advantages for using rats in preclinical efficacy studies compared...

Large-scale synthesis of a Notum inhibitor employing a modified Sakai reaction as the key step

WuXi AppTec scientists recently contributed to a research article in the Royal Society of Chemistry describing the large-scale synthesis of...

Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines

Delivery carriers are a critical component in the development of mRNA vaccines. Here, we describe the synthesis of a cationic...

Knowledge Library